Point-of-Care Glucose Testing Market – By Product Type (Lancing Devices, Test Strips, Blood-Glucose Meter), End-use (Hospital, Clinics, Home Care Settings, Diagnostic Centers) – Global Forecast, 2024 – 2032

Point-of-Care Glucose Testing Market Size

Point-of-Care Glucose Testing Market size was valued at around USD 3.4 billion in 2023 and is estimated to grow at 4.7% CAGR from 2024 to 2032. Point-of-care glucose testing refers to the process of measuring blood glucose levels at or near the site of patient care, rather than in a centralized laboratory. This testing is performed using portable and user-friendly devices that provide immediate results, allowing for quick decision-making in the management of diabetes and other conditions requiring glucose monitoring.
 

The rising incidence of diabetes is a significant driver of market growth. For instance, according to the World Health Organization (WHO), about 422 million people worldwide have diabetes in 2024, with the majority living in low- and middle-income countries, and 1.5 million deaths are directly attributed to diabetes each year. This underscores the urgent need for reliable point-of-care glucose testing solutions to manage the growing diabetes burden effectively.
 

Additionally, technological advancements in glucose monitoring, the rising geriatric population, and the growing adoption of continuous glucose monitors are key factors driving market growth
 

Point-of-Care Glucose Testing Market Trends

Recent advancements in point-of-care (POC) glucose testing have significantly enhanced the accuracy, convenience, and overall management of diabetes. Innovations, ranging from integration with continuous glucose monitoring systems to the development of advanced sensor technologies, are transforming how glucose levels are monitored and managed.
 

• Modern point-of-care glucose meters are increasingly integrating with continuous glucose monitoring systems. This allows for real-time glucose tracking and trend analysis, enhancing diabetes management and providing more comprehensive data to both patients and healthcare providers.
   
• For instance, in February 2023, Dexcom launched its next-generation Dexcom G7 CGM System, featuring a sensor 60% smaller than its predecessor (G6). The G7 provides real-time glucose data directly to smartphones or smartwatches, eliminating the need for fingerstick tests. It is designed for individuals with type 1, type 2, or gestational diabetes.
   
• Many point-of-care glucose meters now include Bluetooth or Wi-Fi capabilities for seamless data transfer to smartphones, tablets, or cloud platforms. This enhances data management and enables remote monitoring by healthcare professionals. For example, Abbott's FreeStyle Libre 3 offers real-time glucose readings through a compact sensor and integrates with the FreeStyle LibreLink app for continuous tracking and data sharing.
   
• Additionally, advancements in biosensor technologies, including non-invasive methods like infrared spectroscopy and radio waves, are being developed to further enhance accuracy and reliability. These innovations aim to eliminate the need for traditional blood samples and advance the overall effectiveness of glucose monitoring, thus propelling market growth.
   

Point-of-Care Glucose Testing Market Analysis

Based on product type, the market is segmented into lancing devices, test strips, and blood-glucose meter. The test strips segment of the market is forecasted to reach USD 2.3 billion by 2032.
 

• Test strips offer high accuracy and precision in glucose measurement, which is essential for effective diabetes management.
   
• Additionally, the user-friendly design of test strips requires minimal training, making them accessible for both patients and healthcare providers. The process involves placing a small blood sample on the strip and inserting it into a glucose meter, facilitating ease of use.
   
• Test strips are relatively inexpensive compared to advanced glucose monitoring technologies, making them a cost-effective option for frequent testing. Their ability to deliver rapid glucose readings is crucial for timely decisions regarding insulin dosing and other management aspects, thereby contributing to market growth.

Based on end-use, the point-of-care glucose testing market is bifurcated into hospitals, clinics, diagnostic centers, home care settings, and other end-users. The home care settings segment accounted for USD 1.3 billion in 2023.
 

• Home care settings offer significant advantages for point-of-care glucose testing. They allow individuals with diabetes to manage their condition conveniently from home, reducing the need for frequent healthcare facility visits.
   
• Moreover, increasing approval from regulatory bodies such as the U.S. FDA for home-based POC glucose testing products is enhancing their availability across the globe, which is contributing to revenue growth in the home care settings segment.
   
• For instance, in March 2024, the U.S. Food and Drug Administration (FDA) approved the Dexcom Stelo Glucose Biosensor System, marking it as the first continuous glucose monitor to be available over-the-counter.

The growth of the point-of-care glucose testing market in the U.S., projected to reach USD 1.9 billion by 2032.
 

• The region has one of the highest prevalence rates of diabetes globally. For instance, according to the Centers for Disease Control and Prevention (CDC), in 2021, over 38.4 million Americans had diabetes, with millions more estimated to have prediabetes. This large patient population drives the demand for diabetes care devices.
   
• The U.S. has a well-established healthcare infrastructure that supports the widespread use of advanced medical technologies, including point-of-care glucose testing devices.
   

The point-of-care glucose testing market in UK is expected to experience significant and promising growth from 2024 to 2032.
 

• The UK benefits from a well-established and sophisticated healthcare infrastructure. The National Health Service (NHS) provides a comprehensive framework for the integration of new medical technologies, including point-of-care (POC) glucose testing systems.
   
• The UK is a hub for medical research and innovation. Numerous universities and research institutions focus on advancing diagnostic technologies, including glucose monitoring. This research contributes to the development of more accurate, efficient, and user-friendly point-of-care glucose testing devices.
   

Japan point-of-care glucose testing market is anticipated to witness lucrative growth between 2024 – 2032.
 

• Japan is renowned for its technological advancements and innovation in the medical device sector. Japanese companies are at the forefront of developing cutting-edge glucose monitoring technologies, including non-invasive and minimally invasive devices.
   
• Japan has one of the world’s most rapidly aging populations, which increases the prevalence of diabetes and the demand for effective glucose monitoring solutions. The growing need for efficient diabetes management drives market growth for point-of-care glucose testing devices.
   

The point-of-care glucose testing market in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• Saudi Arabia is investing significantly in its healthcare infrastructure as part of Saudi Vision 2030, which aims to enhance healthcare services and integrate advanced medical technologies. This investment creates a favorable environment for the adoption of POC glucose testing devices.
   

Point-of-Care Glucose Testing Market Share

The point-of-care (POC) glucose testing industry is characterized by intense competition, with major global companies and smaller to medium-sized firms vying for market leadership. Key strategies for maintaining a competitive edge include the regular introduction of innovative technologies and products. Leading industry players drive innovation through significant investments in research and development.
 

Furthermore, strategic partnerships, acquisitions, and mergers are crucial for consolidating market positions and expanding international reach, enabling companies to enhance their market presence and leverage new opportunities. Smaller players are focusing on specific niches or bringing innovative approaches to POC testing. These companies often target underserved areas or specific medical conditions, creating competitive pressure on established players.
 

Point-of-Care Glucose Testing Market Companies

Some of the eminent market participants operating in the point-of-care glucose testing industry include:

• Abbott Laboratories
• ARKRAY, Inc.
• ACON Laboratories, Inc.
• B. Braun Melsungen AG
• Dexcom, Inc.
• EKF Diagnostics Holdings plc
• F. Hoffmann-La Roche Ltd.
• Medtronic plc
• Nipro Corporation
• Nova Biomedical Corporation
• PHC Holdings
• Prodigy Diabetes Care, LLC.
• Platinum Equity Advisors, LLC.
• Sanofi
• Sinocare
   

Point-of-Care Glucose Testing Industry News:

• In January 2024, Medtronic plc received the CE Mark approval for the MiniMed 780G system with Simplera Sync, a compact, disposable CGM that requires no fingersticks or overtape and features a simplified two-step insertion process. This advancement underscores Medtronic’s commitment to enhancing diabetes management with improved ease of use.
   
• In March 2024, Nova Biomedical launched the New Generation StatStrip Glucose Hospital Meter System in the U.S., showcasing the company’s commitment to enhancing hospital glucose monitoring with improved functionality and increased security.
   

The point-of-care glucose testing market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product Type

• Lancing devices
• Test strips
• Blood-glucose meter

Market, By End-use

• Hospitals
• Clinics
• Diagnostic centers
• Home care settings
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of Middle East and Africa